| Literature DB >> 28903751 |
Tian Liu1,2, Anchun Cheng3,4,5, Mingshu Wang6,7,8, Renyong Jia1,2,9, Qiao Yang1,2,9, Ying Wu1,2,9, Kunfeng Sun1,2,9, Dekang Zhu2,9, Shun Chen1,2,9, Mafeng Liu1,2,9, XinXin Zhao1,2,9, Xiaoyue Chen2,9.
Abstract
Duck plague virus (DPV), a member of alphaherpesvirus sub-family, can cause significant economic losses on duck farms in China. DPV Chinese virulent strain (CHv) is highly pathogenic and could induce massive ducks death. Attenuated DPV vaccines (CHa) have been put into service against duck plague with billions of doses in China each year. Researches on DPV have been development for many years, however, a comprehensive understanding of molecular mechanisms underlying pathogenicity of CHv strain and protection of CHa strain to ducks is still blank. In present study, we performed RNA-seq technology to analyze transcriptome profiling of duck spleens for the first time to identify differentially expressed genes (DEGs) associated with the infection of CHv and CHa at 24 h. Comparison of gene expression with mock ducks revealed 748 DEGs and 484 DEGs after CHv and CHa infection, respectively. Gene pathway analysis of DEGs highlighted valuable biological processes involved in host immune response, cell apoptosis and viral invasion. Genes expressed in those pathways were different in CHv infected duck spleens and CHa vaccinated duck spleens. The results may provide valuable information for us to explore the reasons of pathogenicity caused by CHv strain and protection activated by CHa strain.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28903751 PMCID: PMC5598070 DOI: 10.1186/s13567-017-0456-z
Source DB: PubMed Journal: Vet Res ISSN: 0928-4249 Impact factor: 3.683
Number of reads of all bases detected using RNA-seq in DPV-infected and control ducks
| Library | Number of raw reads | Number of clean reads | Number of uniquely mapped reads | Percentage of reads mapped (%) |
|---|---|---|---|---|
| CHv-1 | 61 196 398 | 58 437 658 | 35 429 191 | 60.63 |
| CHv-2 | 61 868 452 | 59 080 194 | 35 273 016 | 59.7 |
| CHv-3 | 69 529 094 | 66 485 428 | 40 823 382 | 61.4 |
| CHa-1 | 63 045 260 | 60 281 664 | 36 842 779 | 61.12 |
| CHa-2 | 61 100 482 | 58 372 142 | 36 312 302 | 62.21 |
| CHa-3 | 68 613 194 | 65 544 842 | 40 272 899 | 61.44 |
| Control-1 | 64 108 500 | 61 235 756 | 37 298 283 | 60.91 |
| Control-2 | 60 808 456 | 58 101 298 | 35 789 540 | 61.6 |
| Control-3 | 60 864 474 | 57 959 378 | 35 637 789 | 61.49 |
| Total | 571 134 310 | 545 498 360 | 333 679 181 |
Figure 1Differentially expressed genes in different experimental conditions. Heatmap is used to classify gene expression patterns under different experimental conditions and Venn diagram displays a global view on the numbers of differentially expressed genes. A Genes with similar expressed patterns were clustered and showed above in the heatmap. Intensity of color indicates gene expression levels that were normalized according to log10 (FPKM + 1) values. Red color represent high expression level genes and blue color represent low expression level genes. The three major clusters represent CHv infected duck group, CHa vaccinated ducks group and control group. B The overlap of differentially expressed genes of CHv vs Control and CHa vs Control. The number in the diagram indicated gene number refers to each comparison.
A summary of GO term numbers after CHv and CHa infection
| GO terms-BP | GO terms-MF | GO terms-CC | Total terms | |
|---|---|---|---|---|
| DEGs only express in CHv | 1806 | 511 | 341 | 2658 |
| DEGs only express in CHa | 976 | 277 | 226 | 1479 |
| DEGs expressed in CHv and CHa | 697 | 215 | 186 | 1098 |
Figure 2Top 30 Gene ontology (GO) terms of DEGs expressed in CHv infected or CHa vaccinated group. GO-terms were processed under three categories including cellular component (CC), molecular function (MF) and biological process (BP). Top 30 GO terms were selected according p-value < 0.05 A GO annotation of DEGs expressed only in CHv infected group B GO annotation of DEGs expressed only in CHa vaccinated group C GO annotation of DEGs expressed in both CHv infected group and CHa vaccinated group.
Figure 3Top 20 KEGG pathways in CHv infected or CHa vaccinated group. A KEGG pathways of DEGs expressed in CHv infected group. B KEGG pathways of DEGs expressed in CHa vaccinated group. C KEGG pathways of DEGs expressed after CHv and CHa infection.
Genes listed involved in multiple cell biological processes after CHv and CHa infection
| Gene ID | Gene name | Gene description | Source of DEGs |
|---|---|---|---|
| Antigen processing and presentation | |||
| MHC-1 pathway | |||
| 101797502 | MHC1 | Major histocompatibility complex, class I | CHv vs control |
| 101797680 | TAP1 | ATP-binding cassette, subfamily B (MDR/TAP), member 2 | CHv vs control |
| 101797091 | TAP2 | ATP-binding cassette, subfamily B (MDR/TAP), member 3 | CHv vs control |
| 101799108 | β2m | Beta-2-microglobulin | CHv vs control and CHa vs control |
| MHC-II pathway | |||
| 101801019 | LGMN | Legumain | CHv vs control |
| 101803352 | CD74 | CD74 antigen | |
| 101804125 | MHC2 | Major histocompatibility complex, class II | CHv vs control and CHa vs control |
| 101803864 | GILT | Gamma-inducible protein 30 | |
| Cytokine-cytokine receptor interaction | |||
| 101799854 | IFNGR1 | Interferon gamma receptor 1 | CHv vs control |
| 101794299 | CSF2RB | Cytokine receptor common subunit beta | CHv vs control |
| 101791761 | SF18 | Tumor necrosis factor receptor superfamily member 18 | CHv vs control |
| 101799587 | PDGFRB | Platelet-derived growth factor receptor beta | CHv vs control |
| 101801232 | SF21 | Tumor necrosis factor receptor superfamily member 21 | CHv vs control |
| 101795038 | CX3CL1 | C-X3-C motif chemokine 1 | CHa vs control |
| 101790039 | CCL19 | C–C motif chemokine 19 | CHa vs control |
| 101802287 | TGFB3 | Transforming growth factor beta-3 | CHa vs control |
| 101793182 | CNTFR | Granulocyte–macrophage colony-stimulating factor receptor alpha | CHa vs control |
| 101797327 | FLT1 | FMS-like tyrosine kinase 1 | CHa vs control |
| 101792543 | FLT4 | FMS-like tyrosine kinase 4 | CHa vs control |
| 101795963 | IL22RA2 | Interleukin 22 receptor alpha 2 | CHa vs control |
| 101802521 | IL15 | Interleukin 15 | CHv vs control and CHa vs control |
| 101803777 | TNFSF13B | Tumor necrosis factor ligand superfamily member 13B | CHv vs control and CHa vs control |
| 101797830 | EGFR | Epidermal growth factor receptor | CHv vs control and CHa vs control |
| Apoptosis | |||
| 101803461 | PIK3CB | Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha/beta/delta | CHv vs control |
| 101793887 | IL3RB | Cytokine receptor common subunit beta | CHv vs control |
| 101801064 | IKKA | Inhibitor of nuclear factor kappa-B kinase subunit alpha | CHv vs control and CHa vs control |
| 101794069 | CASP6 | Caspase 6 | CHv vs control and CHa vs control |
| Viral invasion | |||
| Cell surface-related receptor | |||
| 101796910 | HSPG2 | Heparan sulfate proteoglycan 2 | CHv vs control |
| 101791819 | HS3ST5 | Heparan sulfate glucosamine 3- | CHv vs control |
| Cell cytoskeletal-related protein | |||
| 101805015 | TUBA1C | Tubulin alpha-1C chain | CHv vs control |
| 101805212 | TUBA1B | Tubulin alpha-1B chain | CHv vs control |
| 101801170 | KIF14 | Kinesin protein KIF14 | CHa vs control |
| 101793497 | ACTA2 | Actin, aortic smooth muscle | CHv vs control |
| 101792376 | ACTG2 | Actin, gamma-enteric smooth muscle | CHv vs control and CHa vs control |
| 101790019 | AFAP1L2 | Actin filament-associated protein 1-like 2 | CHv vs control and CHa vs control |
| 101799368 | MYL9 | Myosin light chain 9 | CHv vs control and CHa vs control |
| 101803563 | MYH11 | Myosin heavy chain 11 | CHa vs control |
| Inner nuclear membrane-related protein | |||
| 101797969 | LMNA | Lamin A/C | CHv vs control and CHa vs control |